VLA1553 full dose + VLA1553 half dose + Control

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chikungunya Virus Infection

Conditions

Chikungunya Virus Infection

Trial Timeline

Dec 18, 2023 → Jul 2, 2025

NCT ID

NCT06106581

About VLA1553 full dose + VLA1553 half dose + Control

VLA1553 full dose + VLA1553 half dose + Control is a phase 2 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT06106581. Target conditions include Chikungunya Virus Infection.

What happened to similar drugs?

0 of 11 similar drugs in Chikungunya Virus Infection were approved

Approved (0) Terminated (2) Active (9)

🔄CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3

🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3

🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3

❌VLA1553Valneva SEPhase 3

🔄Biological Vaccine VLA1553Valneva SEPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06106581	Phase 2	Completed	Dec 18, 2023	Jul 2, 2025	Chikungunya Virus Infection

Competing Products

20 competing products in Chikungunya Virus Infection

See all competitors

Product	Company	Stage	Hype Score
VAL-181388	Moderna	Phase 1	0
mRNA-1944	Moderna	Phase 1	0
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo	Bavarian Nordic	Phase 2	32
Chikungunya	Bavarian Nordic	Phase 2	32
CHIKV VLP vaccine booster + Placebo booster	Bavarian Nordic	Phase 3	41
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	37
CHIKV VLP, adjuvanted	Bavarian Nordic	Phase 2	32
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	37
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	44
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	44
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	26
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	24
Biological Vaccine VLA1553	Valneva SE	Phase 3	34
Active + Placebo	Valneva SE	Phase 3	34
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	38
VLA1553 + Control	Valneva SE	Phase 3	26
VLA1553 + Placebo	Valneva SE	Phase 3	34
VLA1553	Valneva SE	Phase 1	23